Updates in muscular dystrophies;Actualización en distrofias musculares

Revista de Neurologia

Volumn 39, Issue 9, 2004, Pages 860-871

  Erazo Torricelli, Ricardo ^a  

^a HOSPITAL LUIS CALVO MACKENNA   (Chile)

Author keywords

Congenital muscular dystrophy; Duchenne Becker muscular dystrophy; Dystrophin; Limb girdle muscular dystrophy; Merosine; Sarcoglycans

Indexed keywords

ALPHA DYSTROGLICAN; CELL PROTEIN; EMERIN; MEROSIN; PREDNISONE; STEROID; UNCLASSIFIED DRUG; UTROPHIN;

ASSISTED VENTILATION; AUTOSOMAL DOMINANT DISORDER; BRAIN MALFORMATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; EMERY DREIFUSS MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FUKUTIN RELATED PROTEIN DYSTROPHY; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MUSCLE EYE BRAIN DISEASE; MUSCULAR DYSTROPHY; PATHOGENESIS; PHENOTYPE; PHYSIOTHERAPY; PROGNOSIS; PROGRESSIVE MUSCULAR ATROPHY; REVIEW; SYSTEMATIC REVIEW; WALKER WARBURG SYNDROME; WESTERN BLOTTING; X CHROMOSOME LINKED DISORDER;

EID: 10344236029     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3909.2004182     Document Type: Review

References (107)

1. Dubowitz V. Histological and histochemical stains and reactions. In Dubowitz V, ed. Muscle biopsy: a practical approach. 2 ed. London: Bailliere Tindall; 1985. p. 19-40.
2. Koenig M, Hoffmann EP, Bretelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and individuals. Cell 1987; 50: 509-17.
3. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-28.
4. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predict a rod shaped cytoeskeletal protein. Cell 1988; 53: 219-28.
5. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989; 338: 259-62.
6. Bonilla E, Samitt CE, Miranda AF, Hays AP, Salviati G, DiMauro S, et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988; 54: 447-52.
7. Campbell KP. Three muscular dystrophies: loss of cytoeskeleton- extracelular matrix linkage. Cell 1995; 80: 675-9.
8. Emery AEH. The muscular dystrophies. Lancet 2002; 2: 687-95.
9. Mathews DK. Muscular dystrophy overview. Neurol Clin 2003; 21: 795-816.
10. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve 2000; 23: 1456-71.
11. Emery AEH. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromusc Dis 1991; 1: 19-29.
12. Fenichel GM. Flaccid limb weakness in childhood. In Fenichel GM, ed. Clinical pediatric neurology. A signs and symptoms approach. 3 ed. Philadelphia: WB Saunders; 1997. p. 181-2.
13. Hoffman EP, Wang J. Duchenne-Becker muscular dystrophies and the non dystrophic myotonias: paradigms for loss of function and change of function of gene products. Arch Neurol 1993; 50: 1227-37.
14. Nigro G, Comi L, Politano L, Nigro V. Dilated cardiomyopathy of muscular dystrophy: a multifaceted approach to management. Semin Neurol 1995; 15: 90-2.
15. Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999; 9: 339-46.
16. Gospe SM Jr, Lazaro RP, Lava NS, Grootscholten PM, Scott MO, Fischbeck KH. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gen. Neurology 1989; 39: 1277-80.
17. Bieber FR, Hoffman EP. Duchenne and Becker muscular dystrophies: genetics, prenatal diagnosis, and future prospects. Clin Perinatol 1990; 17: 856-7.
18. Engel AG, Yamamoto M, Fischbeck KH. Dystrophinopathies. In Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill; 1994. p. 1134-5.
19. Bies RD, Caskey CT, Fenwick R. An intact cysteine-rich domain is required for dystrophin function. J Clin Invest 1992; 90: 666-71.
20. Michalak M, Opas M. Functions of dystrophin and dystrophin associated proteins. Curr Opin Neurol 1997; 10: 436-42.
21. Ben Hamida M, Fardeau M, Attia N. Severe childhood muscular dystrophy affecting both sexes and frecuent in Tunisia. Muscle Nerve 1983; 6: 469-80.
22. Merlini L, Kaplan JC, Navarro C, Barois A, Bonneau D, Brasa J, et al. Homogeneus phenotype of the gypsy limb-girdle MD with γ-sarcoglican C283Y mutation. Neurology 2000; 54: 1075-9.
23. Hauser MA, Conde CB, Kowaljow V, Zeppa G, Taratuto AL, Torian UM, et al. Myotilin mutation found in second pedigree with LGMD1A. Am J Hum Genet 2002; 71: 1428-32.
24. Salmikangas P, van der Ven PF, Lalowsky M, Taivainen A, Zhao F, Suila H, et al. Myotilin, the limb-girdle muscular dystrophy 1 A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum Mol Genet 2003; 12: 189-203.
25. Carbone I, Bruno C, Sotgia F, Bado M, Broda P, Masetti E, et al. Mutations in caveolin-3 gene causes a peculiar form of distal myopathy. Neurology 2002; 58: 323-5.
26. Betz RC, Schoser BG, Kasper D, Ricker K, Ramírez A, Stein V, et al. Mutations in CAV 3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001; 28: 218-9.
27. Vorgerd M, Ricker K, Ziemssen F, Kress W, Goebel HH, Nix WA, et al. A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 2001; 57: 2273-7.
28. Colomer J. Sarcoglicanopatías. Rev Neurol 1999; 28: 150-3.
29. Angelini C, Fanin M, Freda MP, Duggan DJ, Siciliano G, Hoffman EP. The clinical spectrum of sarcoglycanopathies. Neurology 1999; 52: 176-9.
30. Politano L, Nigro V, Pasamano L, Petretta V, Comi LI, Papparella S, et al. Evaluation of cardiac and respiratory involvement in sarcoglicanopathies. Neuromuscul Disord 2001; 11: 178-85.
31. Urtasun M, Poza JJ, Gallano P, Lasa A, Sáez A, Cobo AM, et al. Distrofia muscular por deficit de la sub unidad α-sarcoglicano del complejo de proteínas relacionadas con la distrofina. Med Clin 1998; 110: 538-42.
32. Bonnemann CG, Finkel RS. Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. Semin Pediatr Neurol 2002; 9: 81-99.
33. Moreira ES, Vainzof M, Suzuki OT, Pavanello RCM, Zats M, Passos-Bueno MR. Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations. J Med Genet 2003; 40; 12.
34. Eirís-Puñal J, Pintos-Martínez E, Lasa A, Gallana P, Castro-Gago M. Distrofia muscular por déficit de γ sarcoglicano. Aportación de 3 pacientes con la mutación Δ 521T. Rev Neurol 2002; 34: 486-9.
35. Moreira ES, Vainzof M, Marie SK, Nigro V, Zatz M, Passos-Bueno MR. A first missense mutation in the delta sarcoglican gene associated with severe phenotype and frequency of limb-girdle muscular dystrophy type2F. (LGMD2F) in Brazilian sarcoglycanopathies. J Med Genet 1998; 35: 951-3.
36. Weiler T, Bashir R, Anderson LV, Davison K, Moss JA, Britton S, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshy myopathy suggests a role for modifier gene (s). Hum Mol Genet 1999; 8: 871-7.
37. Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, Nylen E, Sukhorukov VS, Poleshchuk VV, et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000; 55: 1931-3.
38. Bushby KM. Dysferlin and muscular dystrophy. Acta Neurol Belg 2000; 100: 142-5.
39. Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann Neurol 2000; 48: 902-12.
40. Fardeau M, Eymard B, Mignard C, Tome FM, Richard I, Beckmann JS. Cromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul Disord 1996; 6: 447-53.
41. Fardeau M, Hillary D, Mignard C, Feingold N, Feingold J, Mignard D, et al. Juvenile limb-girdle muscular dystrophy: clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996; 119: 295-308.
42. Richard I, Breuguier L, Dincer P, Roudaut C, Bady B, Burgunder JM, et al. Multiple independent molecular etiology for LGMD2A patients from various geographical origins. Am J Hum Genet 1997; 60: 1128-38.
43. López de Munain A, Urtasun A, Poza JJ, Ruiz J, Sáenz A, Cobo AM, et al. Alteraciones en las proteínas funcionales. Déficit de calpaína 3. Rev Neurol 1999; 28: 154-8.
44. Spencer MJ, Guyon JR, Sorimachi H, Potts A, Richard I, Herasse M, et al. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggest a role for calpain 3 in muscle maturation. Proc Natl Acad Sci U S A 2002; 99: 8874-9.
45. Sorimachi H, Ono Y, Suzuki K. Skeletal muscle-specific calpain p94, and connectin/titin: their physiological functions and relationship to limb-girdle muscular dystrophy type 2A. Adv Exp Med Biol 2000; 481: 383-95.
46. Wehnert MS, Bonne G. The nuclear muscular dystrophies. Semin Pediatr Neurol 2002; 9: 100-7.
47. Bonne G. La saga de las laminopatías. Rev Neurol 2003; 37: 772-4.
48. Emery AEH. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. Neuromuscul Disord 2000; 10; 228-32.
49. Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamina/C gene. Ann Neurol 2000; 48: 170-80.
50. Fairley EA, Kendrick-Jones J, Ellis JA. The Emery-Dreifuss muscular dystrophy phenotype arises from aberrant targeting and binding of emerin at the inner nuclear membrane. J Cell Sci 1999; 112: 3571-82.
51. Bonne G, Di Barletta MR, Varnous S, Became HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamina A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nature Genet 1999; 21: 285-8.
52. Raffaelle-Di Barletta M, Ricci E, Galluzi G, Tonali P, Mora M, Morandi L, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000; 66: 1407-12.
53. Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 1994; 51: 387-94.
54. Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology 1998; 50: 1791-4.
55. Krasnianski M, Eger K, Neudecker S, Jakubiczka S, Zierz S. Atypical phenotypes in patients with facioscapulohumeral muscular dystrophy 4q35 deletion. Arch Neurol 2003; 60: 1421-5.
56. Van Deutekom JC. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993; 2: 1791-4.
57. Deidda G, Cacurri S, Piazzo N, Felicetti L. Direct detection of 4q35 rearrangements implicated in facioscapulohumeral dystrophy (FSHD). J Med Genet 1996; 33: 361-5.
58. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2003; 110: 339-48.
59. Mercuri E, Sewry C, Brown S, Muntoni F. Congenital muscular dystrophies. Semin Pediatr Neurol 2002; 9: 120-31.
60. Smeyers P. Distrofias musculares por alteration en el espacio extracelular: distrofia muscular congénita por déficit de merosina. Rev Neurol 1999; 28: 141-9.
61. Van der Knaap MS, VaIk J. Congenital muscular dystrophy. In: Magnetic resonance of myelin, myelination and myelin disorders. 2 ed. New York: Springer; 1995. p. 267-76.
62. Mercuri E, Dubowits L, Berardinelli A, Pennock J, Jongmans M, Henderson S, et al. Minor neurological and perceptuo-motor deficits in children with congenital muscular dystrophy: correlation with brain MRI changes 1995; 26: 156-62.
63. Mercuri E, Muntoni F, Berardinelli A, Pennock J, Sewry C, Philpot J, et al. Somato sensory and visual evoked potentials in congenital muscular dystrophy: correlations with MRI changes and muscle merosin status. Neuropediatrics 1995; 26: 3-7.
64. Sunada Y, Edgar TS, Lotz BP, Rust RS, Campbell KP. Laminin alpha 2 chain negative congenital muscular dystrophy associated with extensive brain abnormalities. Neurology 1995; 45: 2084-9.
65. Taratuto AL, Lubieniecki D, Díaz D, Schultz M, Ruggieri V, Saccoliti M, et al. Merosin-deficient congenital muscular dystrophy associated with abnormal cerebral cortical gyration: an autopsy study. Neuromuscul Disord 1999; 9: 86-94.
66. Gilhuis HJ, Ten Donkelaar HJ, Tanke RB, Binguerotes DM, Zwarts MJ, Verrips A, et al. Nonmuscular involvement in merosin-negative congenital muscular dystrophy. Pediatr Neurol 2002; 26: 30-6.
67. Jones KJ, Morgan G, Johnston H, Tobías V, Ouvrier RA, Wilkinson I, et al. The expanding phenotype of laminin alpha 2 chain (merosin) abnormalities: case series and review. J Med Genet 2001; 38: 649-57.
68. Topaloglu H, Brockington M, Yuva Y, Talim B, Haliloglu G, Blake D, et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 2003; 25: 988-92.
69. Poppe M, Cree L, Bourke J, Eagle M, Anderson LVB, Birchall D, et al. The phenotype of limb-girdle muscular dystrophy type 21. Neurology 2003; 60: 1246-51.
70. th ENM sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies. Neuromuscul Disord 2002; 13: 80-90.
71. Flanigan KM, Kerr L, Bromberg MB, Leonard C, Tsuruda J, Zhang P, et al. Congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study. Ann Neurol 2000; 47: 152-61.
72. Moghadaszadeh B, Desguerre I, Topaloglu H, Muntoni F, Pavek S, Sewry C, et al. Identification of a new locus for a peculiar form of congenital muscular dystrophy with early rigidity of the spine, on chromosome 1p35-36. Am J Hum Genet 1998; 62: 1439-45.
73. Moghadaszadeh B, Petit N, Jaillard C, Brockington M, Roy SQ, Merlini L. et al. Mutation in SEPN1 cause congenital muscular dystrophy with spinal rigidity restrictive respiratory syndrome. Nat Genet 2001; 29: 17-8.
74. Ullrich O. Kongenitale atonish-sklerotische Muskeldystrophie. Monatsschr Kinderheilkd 1930; 47: 502-10.
75. Mercuri E, Yuva Y, Brown SC, Brockington M, Kinali M, Jungbluth H, et al. Collagen VI involvement in Ullrich syndrome: a clinical, genetic and immunohistochemical study. Neurology 2002; 58: 1354-9.
76. Camacho-Vanegas O, Bertini E, Zhang RZ, Petrini S, Minosse C, Sabatelli P, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in the collagen type VI. Proc Natl Acad Sci U S A 2001; 98: 7516-21.
77. Higuchi I, Shiraishi T, Hashiguchi T, Suehara M, Niiyama T, Nakagawa M, et al. Frameshift mutation in the collagen VI gene cause Ullrich's disease. Ann Neurol 2001; 50: 261-5.
78. Hu J, Higuchi I, Shiraishi T, Suehara M, Niiyama T, Horikiri T, et al. Fibronectin receptor reduction in skin and fibroblasts of patients with Ullrich's disease. Muscle Nerve 2002; 26: 696-701.
79. Merlini L, Morandi L, Granata C, Ballestrazzi A. Bethlem myopathy: early-onset benign autosomal dominant myopathy with contractures. Description of two new families. Neuromuscul Disord 1994; 4: 503-11.
80. th ENMC international workshop, 10-11 November 2000, Naarden, The Nederlands. Neuromuscul Disord 2002; 12: 296-305.
81. Michele DE, Barrresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002; 418: 417-22.
82. Fukuyama Y, Kawasura M, Haruna H. A peculiar form of congenital progressive muscular dystrophy. Report of fifteen cases. Paediatr Univ Tokyo 1960; 4: 5-8.
83. Fukuyama Y, Osawa M, Saito K. Congenital muscular dystrophies: an overview. In Arzimanoglou A, Goutieres F, eds. Trends in child neurology. Paris: John Libbey Eurotext; 1996. p. 107-35.
84. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, et al. An ancient retrotransportal insertion cause Fukuyama-type congenital muscular dystrophy. Nature 1998; 394: 388-92.
85. Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001; 57: 115-21.
86. Cormand B, Pihko H, Bayes M, Valanne L, Santavouri P, Talim B, et al. Clinical and genetic distinction between Walker-Warburg syndrome and muscle-eye-brain disease. Neurology 2001; 56: 1059-69.
87. Cormand B, Avela K, Pihko H, Santavouri P, Talim B, Topaloglu H, et al. Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping. Am J Hum Genet 1999; 64: 126-35.
88. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001; 1: 717-24.
89. Beltrán-Valero de Bernabé D, Currier S, Steinbrecher A, Celli J, van Beusekom E, van der Zwaag B, et al. Mutations in the O-mannsyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002; 71: 1033-43.
90. Jones KJ, Compton AG, Yang N, Mills MA, Peters MF, Mowat, et al. Deficiency of the syntrophins and α dystrobrevin in patients with inherited myopathy. Neuromuscul Disord 2003; 13: 457-67.
91. Mercuri E, Cini C, Pichiecchio A, Allsop J, Counsell S, Zolkipli Z, et al. Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype. Neuromuscul Disord 2003; 13: 554-8.
92. Mercuri E, Talim B, Moghadaszadeh B, Petit N, Brockington M, Counsell S, et al. Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1). Neuromuscul Disord 2002; 12: 631-8.
93. Jiménez-Mallebrera C, Torelli S, Brown SC, Feng L, Brockington M, Sewry CA, et al. Profound skeletal muscle depletion of α-dystroglycan in Walker-Warburg syndrome. Eur J Pediatr Neurol 2003; 7: 129-37.
94. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown R. A novel, blood-based diagnostic assay for limb gird1 muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002; 51: 129-33.
95. Castro-Gago M, Novo-Rodríguez MI, Pintos-Martínez E, Gallano P, Eirís-Puñal J. Adhalinopatía primaria (LGMD2D) de inicio en los primeros meses de vida que simula una distrofia muscular congénita. Rev Neurol 2001; 32: 631-5.
96. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2: 731-40.
97. Whittock NV, Roberts RG, Mathew CG, Abbs SJ. Dystrophin point mutation screening using a multiplexed protein truncation test. Genet Test 1997; 1: 115-23.
98. Skuk D, Vilquin JT, Tremblay JP. Experimental and therapeutic approaches to muscular dystrophies. Curr Opin Neurol 2002; 15: 563-9.
99. Connolly AM, Schierbecker J, Renna R, Florence H. High dosis weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12: 917-25.
100. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002; 12(Suppl 1): S169-74.
101. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23: 1344-7.
102. Campbell C, Jacob P. Deflazacort for treatment of Duchenne dystrophy: a systematic review. BMC Neurology 2003; 3: 7-16.
103. Karpati G, Lochmuller H. When running a stop sign may be a good thing. Ann Neurol 2001; 49: 693-4.
104. Perkins KJ, Burton EA, Davies KE. The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy. Nucleic Acids Res 2001; 29: 4843-50.
105. Eagle M, Baudoin V, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12: 926-9.
106. Mummery CJ, Copeland SA, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database of Sistematic Reviews; 2003. p. 3.
107. Dubowitz V. What is muscular dystrophy? Forty years of progressive ignorance. J R Coll Physicians Lond 2000; 34: 464-8.